KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Interest & Investment Income: 2018-2025

Historic Interest & Investment Income for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $73.0 million.

  • Moderna's Interest & Investment Income fell 29.13% to $73.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.0 million, marking a year-over-year decrease of 23.34%. This contributed to the annual value of $425.0 million for FY2024, which is 0.95% up from last year.
  • Latest data reveals that Moderna reported Interest & Investment Income of $73.0 million as of Q3 2025, which was down 9.88% from $81.0 million recorded in Q2 2025.
  • Moderna's Interest & Investment Income's 5-year high stood at $120.0 million during Q1 2024, with a 5-year trough of $3.0 million in Q2 2021.
  • Its 3-year average for Interest & Investment Income is $99.1 million, with a median of $103.0 million in 2024.
  • In the last 5 years, Moderna's Interest & Investment Income tumbled by 57.14% in 2021 and then spiked by 1,350.00% in 2022.
  • Over the past 5 years, Moderna's Interest & Investment Income (Quarterly) stood at $7.0 million in 2021, then surged by 1,142.86% to $87.0 million in 2022, then increased by 18.39% to $103.0 million in 2023, then decreased by 11.65% to $91.0 million in 2024, then fell by 29.13% to $73.0 million in 2025.
  • Its last three reported values are $73.0 million in Q3 2025, $81.0 million for Q2 2025, and $90.0 million during Q1 2025.